Momenta And Sandoz Pay $120m To Settle Enoxaparin Suit
Result Of Class-Action Suit ‘Extraordinary,’ Court Hears
Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.
You may also be interested in...
Zydus Cadila has partnered with an Italian manufacturer to launch a generic version of preservative free Lovenox. Days earlier, the Indian firm’s management had discussed its hopes and expectations for its fledgling US injectables business.
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.